| ACCUEIL  | LES MEDECINS  | LES PATHOLOGIES  | LES TRAITEMENTS  | LA CONSULTATION  | NEWS  | CONTACT  | PRENDRE RDV EN LIGNE

Alain Zourdani

  • Assistant Spécialiste à l’Hôpital Intercommunal de Créteil.
  • Prix Christian ZWENG, décerné par la Société Française de Rétine en 2004.
  • Activités de recherche clinique, participation à des protocoles de recherche en qualité de médecin expert investigateur
  • Secrétaire général adjoint de la société française de lutte contre les pathologies oculaires cécitantes et le trachome.
  • Expert International auprès du DARC (DARC Members) Manhattan, New York, USA.
  • Expert National auprès de l’Agence Nationale d’Accréditation et d’Evaluation en Santé (ANAES).
  • Expert National auprès de la Haute Autorité de Santé (HAS)

Lieux de Consultation : DRAGUIGNAN RETINA

Co-auteurs de livres

Rapport Société Ophtalmologie de France 2004, 2008, 2011.

Rapport de la Société Française d’Ophtalmologie en 2007.

Articles scientifiques

Querques G, Merle BM, Pumariega NM, Benlian P, Delcourt C, Zourdani A, Leisy HB, Lee MD, Smith RT, Souied EH. Dynamic Drusen Remodelling in Participants of the Nutritional AMD Treatment-2 (NAT-2) Randomized Trial. PLoS One. 2016 Feb 22;11(2):e0149219.

Landré C, Zourdani A, Gastaud P, Baillif S. [Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant]. J Fr Ophtalmol. 2016 Jan;39(1):5-11.

Atmani K, Querques G, Zourdani A, Benhamou N, Souied EH. Unusual presentations of type 2 idiopathic macular telangiectasia. Ophthalmologica. 2013;230(3):126-30.

Souied EH, Delcourt C, Querques G, Bassols A, Merle B, Zourdani A, Smith T, Benlian P; Nutritional AMD Treatment 2 Study Group. Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study. Ophthalmology. 2013 Aug;120(8):1619-31.

Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Queré S, Schneider V; LUMIERE Study Group. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013 Mar;33(3):474-81.

Martinet V, Guigui B, Glacet-Bernard A, Zourdani A, Coscas G, Soubrane G, Souied EH. Macular edema in central retinal vein occlusion: correlation between optical coherence tomography, angiography and visual acuity. Int Ophthalmol. 2012 Aug;32(4):369-77.

Glacet-Bernard A, Coscas G, Zourdani A, Soubrane G, Souied EH. Steroids and macular edema from retinal vein occlusion. Eur J Ophthalmol. 2011;21 Suppl 6:S37-44.

Puche N, Glacet A, Mimoun G, Zourdani A, Coscas G, Soubrane G. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. Acta Ophthalmol. 2012 Jun;90(4):357-61.

Angulo Bocco MC, Glacet-Bernard A, Zourdani A, Coscas G, Soubrane G. [Intravitreous injection: retrospective study on 2028 injections and their side effects]. J Fr Ophtalmol. 2008 Sep;31(7):693-8. French.

Leveziel N, Souied EH, Richard F, Barbu V, Zourdani A, Morineau G, Zerbib J, Coscas G, Soubrane G, Benlian P. PLEKHA1-LOC387715-HTRA1 polymorphisms and exudative age-related macular degeneration in the French population. Mol Vis. 2007 Nov 26;13:2153-9.

Nkeme J, Glacet-Bernard A, Gnikpingo K, Zourdani A, Mimoun G, Mahiddine H, Gkoritsa A, Tchamo A, Coscas G, Soubrane G. [Surgical treatment of persistent macular edema in retinal vein occlusion]. J Fr Ophtalmol. 2006 Sep;29(7):808-14.

Le Tien V, Souied E, d’Athis P, Haddad W, Zourdani A, Mahiddine H, Coscas G, Soubrane G. [SPA-1: semiology for phenotyping AMD: precursors]. J Fr Ophtalmol. 2006 Sep;29(7):796-802.

Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG; DX-Retinopathy Study Group. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol. 2006 Dec;244(12):1591-600.

Glacet-Bernard A, Zourdani A, Perrenoud F, Coscas G, Soubrane G. Stage 3 macular hole: role of optical coherence tomography and of B-scan ultrasonography. Am J Ophthalmol. 2005 May;139(5):814-9.

Coscas G, Coscas F, Zourdani A, Soubrane G. [Optical coherence tomography and ARMD]. J Fr Ophtalmol. 2004 Nov;27(9 Pt 2):3S7-30. French.

Glacet-Bernard A, Zourdani A, Milhoub M, Maraqua N, Coscas G, Soubrane G. Effect of isovolemic hemodilution in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2001 Dec;239(12):909-14.

Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology. 1996 Apr;103(4):551-60.

Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol. 1994 Oct 15;118(4):421-9.

Glacet-Bernard A, Mahdavi KN, Coscas G, Zourdani A, Fardeau C. Macular grid photocoagulation in persistent macular edema due to central retinal vein occlusion. Eur J Ophthalmol. 1994 Jul-Sep;4(3):166-74.